Hepatic impairment alters drug pharmacokinetics by reducing the liver’s capacity to metabolize drugs and by affecting protein synthesis, blood flow, and biliary excretion. Unlike renal impairment, where creatinine clearance provides a reliable biomarker for dose adjustment, hepatic impairment lacks a similarly straightforward quantitative measure. The liver performs diverse functions, and the degree of impairment in one function may not correlate with impairment in others, making dose adjustment in liver disease particularly challenging.
Assessment of Hepatic Function
The Child-Pugh score is the most commonly used tool for classifying the severity of hepatic impairment. It incorporates five variables: serum bilirubin, serum albumin, prothrombin time or international normalized ratio, presence of ascites, and presence of hepatic encephalopathy. Each variable is scored from 1 to 3, and the total score classifies patients into class A (mild, score 5 to 6), class B (moderate, score 7 to 9), or class C (severe, score 10 to 15). Regulatory guidelines for drug development recommend pharmacokinetic studies in patients with each Child-Pugh class to guide dosing recommendations.
However, the Child-Pugh score has limitations for drug dosing. It does not directly measure the activity of specific drug-metabolizing enzymes, and the correlation between Child-Pugh class and the clearance of individual drugs varies considerably. Cytochrome P450 enzymes may be differentially affected by liver disease, with CYP2C19 and CYP1A2 generally more affected than CYP2D6 and CYP2E1. This differential effect means that knowledge of the specific metabolic pathway is important for predicting the impact of hepatic impairment on a particular drug.
Impact on Drug Metabolism
Hepatic impairment reduces the intrinsic clearance capacity of hepatocytes, which primarily affects drugs with low hepatic extraction ratios. For these capacity-limited drugs, hepatic impairment reduces clearance disproportionately to changes in liver blood flow. The fraction of unbound drug may also increase if albumin synthesis is reduced, which can transiently increase the free drug concentration and alter the pharmacological effect.
For drugs with high hepatic extraction ratios, clearance is primarily determined by liver blood flow rather than intrinsic enzyme activity. In cirrhosis, intrahepatic shunts and reduced portal blood flow can decrease hepatic clearance of these drugs. However, the reduction in clearance for high-extraction drugs is generally less severe than for low-extraction drugs because the extraction ratio remains high despite enzyme dysfunction.
Dose Reduction Strategies
When dose adjustment is necessary, the approach depends on the drug’s pharmacokinetic characteristics and the severity of hepatic impairment. A common recommendation is to reduce the dose by 25% in Child-Pugh class A, 50% in class B, and to avoid the drug or use extreme caution in class C. However, these general guidelines must be supplemented by drug-specific recommendations from the prescribing information.
For drugs that undergo extensive first-pass metabolism, hepatic impairment can paradoxically increase oral bioavailability by reducing presystemic clearance. A drug that normally has low oral bioavailability due to extensive first-pass metabolism may achieve much higher systemic concentrations in cirrhotic patients, requiring a substantial reduction in oral dose. This is the case for drugs such as verapamil, nifedipine, and many opioids.
Monitoring Recommendations
Because of the unpredictability of pharmacokinetic changes in hepatic impairment, therapeutic drug monitoring is highly recommended when available. Drugs with narrow therapeutic indices that are primarily hepatically metabolized, such as theophylline, phenytoin, and cyclosporine, require particularly careful monitoring. Clinical assessment of drug effect and toxicity should guide dose titration in the absence of reliable concentration measurements.
Patients with hepatic impairment are also at increased risk of adverse effects that are not directly related to drug accumulation. Coagulopathy from reduced synthesis of clotting factors increases the risk of bleeding from anticoagulants and antiplatelet agents. Hepatic encephalopathy can be precipitated by sedatives and drugs that affect the central nervous system. Ascites and edema alter the volume of distribution of hydrophilic drugs.
Challenges in Hepatic Dosing
The major challenge in hepatic dosing is the lack of a simple, universally applicable biomarker that correlates with drug-metabolizing capacity. Endogenous markers such as the antipyrine clearance test or the lidocaine metabolite test have been proposed but are not routinely used. Furthermore, hepatic impairment is often complicated by concomitant renal impairment, hypoalbuminemia, and altered body composition, each of which independently affects drug disposition.
Despite these challenges, a systematic approach that considers the severity of hepatic impairment, the drug’s metabolic pathway and therapeutic index, and the availability of monitoring options allows clinicians to dose drugs more safely in patients with liver disease.
